266 related articles for article (PubMed ID: 17444623)
1. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
Prongay AJ; Guo Z; Yao N; Pichardo J; Fischmann T; Strickland C; Myers J; Weber PC; Beyer BM; Ingram R; Hong Z; Prosise WW; Ramanathan L; Taremi SS; Yarosh-Tomaine T; Zhang R; Senior M; Yang RS; Malcolm B; Arasappan A; Bennett F; Bogen SL; Chen K; Jao E; Liu YT; Lovey RG; Saksena AK; Venkatraman S; Girijavallabhan V; Njoroge FG; Madison V
J Med Chem; 2007 May; 50(10):2310-8. PubMed ID: 17444623
[TBL] [Abstract][Full Text] [Related]
2. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.
Venkatraman S; Bogen SL; Arasappan A; Bennett F; Chen K; Jao E; Liu YT; Lovey R; Hendrata S; Huang Y; Pan W; Parekh T; Pinto P; Popov V; Pike R; Ruan S; Santhanam B; Vibulbhan B; Wu W; Yang W; Kong J; Liang X; Wong J; Liu R; Butkiewicz N; Chase R; Hart A; Agrawal S; Ingravallo P; Pichardo J; Kong R; Baroudy B; Malcolm B; Guo Z; Prongay A; Madison V; Broske L; Cui X; Cheng KC; Hsieh Y; Brisson JM; Prelusky D; Korfmacher W; White R; Bogdanowich-Knipp S; Pavlovsky A; Bradley P; Saksena AK; Ganguly A; Piwinski J; Girijavallabhan V; Njoroge FG
J Med Chem; 2006 Oct; 49(20):6074-86. PubMed ID: 17004721
[TBL] [Abstract][Full Text] [Related]
3. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.
Llinàs-Brunet M; Bailey MD; Ghiro E; Gorys V; Halmos T; Poirier M; Rancourt J; Goudreau N
J Med Chem; 2004 Dec; 47(26):6584-94. PubMed ID: 15588093
[TBL] [Abstract][Full Text] [Related]
4. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
[TBL] [Abstract][Full Text] [Related]
5. Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034.
Madison V; Prongay AJ; Guo Z; Yao N; Pichardo J; Fischmann T; Strickland C; Myers J; Weber PC; Beyer BM; Ingram R; Hong Z; Prosise WW; Ramanathan L; Taremi SS; Yarosh-Tomaine T; Zhang R; Senior M; Yang RS; Malcolm B; Arasappan A; Bennett F; Bogen SL; Chen K; Jao E; Liu YT; Lovey RG; Saksena AK; Venkatraman S; Girijavallabhan V; Njoroge FG
J Synchrotron Radiat; 2008 May; 15(Pt 3):204-7. PubMed ID: 18421139
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
Vendeville S; Nilsson M; de Kock H; Lin TI; Antonov D; Classon B; Ayesa S; Ivanov V; Johansson PO; Kahnberg P; Eneroth A; Wikstrom K; Vrang L; Edlund M; Lindström S; Van de Vreken W; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Van Dooren M; Kindermans N; Surleraux D; Wigerinck P; Rosenquist A; Samuelsson B; Simmen K; Raboisson P
Bioorg Med Chem Lett; 2008 Dec; 18(23):6189-93. PubMed ID: 18954982
[TBL] [Abstract][Full Text] [Related]
7. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
[TBL] [Abstract][Full Text] [Related]
9. The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease.
Ontoria JM; Di Marco S; Conte I; Di Francesco ME; Gardelli C; Koch U; Matassa VG; Poma M; Steinkühler C; Volpari C; Harper S
J Med Chem; 2004 Dec; 47(26):6443-6. PubMed ID: 15588076
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
[TBL] [Abstract][Full Text] [Related]
11. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.
Arasappan A; Njoroge FG; Chan TY; Bennett F; Bogen SL; Chen K; Gu H; Hong L; Jao E; Liu YT; Lovey RG; Parekh T; Pike RE; Pinto P; Santhanam B; Venkatraman S; Vaccaro H; Wang H; Yang X; Zhu Z; Mckittrick B; Saksena AK; Girijavallabhan V; Pichardo J; Butkiewicz N; Ingram R; Malcolm B; Prongay A; Yao N; Marten B; Madison V; Kemp S; Levy O; Lim-Wilby M; Tamura S; Ganguly AK
Bioorg Med Chem Lett; 2005 Oct; 15(19):4180-4. PubMed ID: 16087332
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants.
Perni RB; Farmer LJ; Cottrell KM; Court JJ; Courtney LF; Deininger DD; Gates CA; Harbeson SL; Kim JL; Lin C; Lin K; Luong YP; Maxwell JP; Murcko MA; Pitlik J; Rao BG; Schairer WC; Tung RD; Van Drie JH; Wilson K; Thomson JA
Bioorg Med Chem Lett; 2004 Apr; 14(8):1939-42. PubMed ID: 15050632
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
[TBL] [Abstract][Full Text] [Related]
15. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
Bogen SL; Pan W; Ruan S; Nair LG; Arasappan A; Bennett F; Chen KX; Jao E; Venkatraman S; Vibulbhan B; Liu R; Cheng KC; Guo Z; Tong X; Saksena AK; Girijavallabhan V; Njoroge FG
J Med Chem; 2009 Jun; 52(12):3679-88. PubMed ID: 19456105
[TBL] [Abstract][Full Text] [Related]
16. Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.
Nair LG; Bogen S; Ruan S; Pan W; Pike R; Tong X; Cheng KC; Guo Z; Doll RJ; Njoroge FG
Bioorg Med Chem Lett; 2010 Mar; 20(5):1689-92. PubMed ID: 20149655
[TBL] [Abstract][Full Text] [Related]
17. Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity.
Bogen SL; Ruan S; Liu R; Agrawal S; Pichardo J; Prongay A; Baroudy B; Saksena AK; Girijavallabhan V; Njoroge FG
Bioorg Med Chem Lett; 2006 Mar; 16(6):1621-7. PubMed ID: 16387495
[TBL] [Abstract][Full Text] [Related]
18. Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease.
White PW; Llinas-Brunet M; Bös M
Prog Med Chem; 2006; 44():65-107. PubMed ID: 16697895
[No Abstract] [Full Text] [Related]
19. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.
Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V
J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919
[TBL] [Abstract][Full Text] [Related]
20. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
